Drug Trial Radar · NCT07397468
To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)
Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Feb 28, 2026
Primary completion
Jul 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Juvena TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-blind, placebo-controlled, randomized study of 96 days total duration to assess the effect of JUV-161 on muscle disuse atrophy. This will be a multicenter study in New Zealand and will include up to 40 healthy volunteers aged between 40 to 65 years of age. Following the screening period, subjects will be randomized to receive either weekly subcutaneous (SC) injections of one of two doses of JUV-161 or matching placebo for a period of approximately 6 weeks.
Conditions
- Healthy Volunteers
Interventions
JUV-161Drug
JUV-161 administered subcutaneously at protocol-specified dose levels.
PlaceboDrug
Matched placebo administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: from enrollment through to Day 96
- Number of Participants who have Change in Quadriceps Muscle Mass and Volume as assessed by magnetic resonance imaging MRI.Time frame: Change from baseline (pre-treatment) to Day 15 (post-immobilization) and Day 45 (post-treatment)
- Number of participants who have Change in lower limb muscle architecture as assessed by MRI.Time frame: Change from baseline (pre-treatment) to Day 15 (post-immobilization) and Day 45 (post-treatment)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Auckland, New Zealand · Recruiting
New Zealand Clinical Research
Christchurch, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.